| Ytd | -24.04% | |
| 1y | 46.68% |
| Open | 5.82 | Prev Close | 5.75 | Low | 5.56 | High | 6.10 | Mkt Cap | 54.17M |
| Vol | 66.68K | Avg Vol | 185.45K | EPS | -23.01 | P/E | N/A | Forward P/E | N/A |
| Beta | 2.11 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 6.82 | 200-d Avg | 7.65 | 1yr Est | 0.00 |
LONA News
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's re
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's r
Athira Pharma, Inc. (NASDAQ: LONA - Get Free Report) shares traded down 34.9% during mid-day trading
Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's r
BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage b
On August 26, 2026, LeonaBio, Inc. (the "Company") announced that it had enrolled the 500th
Mizuho analyst Graig Suvannavejh maintains LeonaBio (NASDAQ:LONA) with a Outperform and lowers th
Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lo
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(0.80) per share which beat the analyst consens
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (E
LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the developmen
BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage bi
Citizens analyst Jason N. Butler upgrades LeonaBio (NASDAQ:LONA) from Market Perform to Market Ou
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar
BOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage bi
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage bio
Piper Sandler analyst Kelsey Goodwin initiates coverage on LeonaBio (NASDAQ:LONA) with a Overweig
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(1.73) per share which beat the analyst consens
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a
BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage bio
LeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Brea
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enr
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(2.77) per share which missed the analyst conse
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Mo
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) a
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) a
Athira Pharma (NASDAQ: LONA - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report)
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report)
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) a
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report)
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) a
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) a
Brings more than 25 years of biopharma business development and corporate strategy expertise Brings
LeonaBio, Inc. 58,464,567 Shares of Common StockOffered by the Selling StockholdersThis prospectus r